Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). This is an ASCO ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA® (pembrolizumab) plus ...
—Using multimodal imaging, this 10-year prospective cohort study identified markers that could help stratify patients at high risk of progressing to advanced AMD, which may help inform clinical ...